|
Hello – Today, we’re inviting you to take a free look at MarketBeat’s proprietary, up-to-the-minute list of 20 stocks that Wall Street’s top-rated analysts hate. These aren’t mild downgrades or lukewarm opinions.
These are true Strong Sell stocks. Some of them may look fine on the surface. A few even have what appear to be solid fundamentals. But when analysts issue a rare Sell rating, it’s usually because something beneath the surface is deeply wrong. Sell-side analysts may not nail every Buy call… but when they raise red flags, they’re almost always worth listening to. If any of these stocks are lurking around in your portfolio, you may seriously want to consider dumping them.
Click here to see the list now. Stay one step ahead, Matthew Paulson
Founder & CEO, MarketBeat
P.S. Access to 20 Stocks to Sell Now is completely free. Don’t miss your chance to review these timely, high-conviction warnings before the market reacts.
Special Report
3 Non-Pharma Firms That Could Benefit From the GLP-1 TrendAuthored by Nathan Reiff. Posted: 6/20/2026. 
Key Points
- With the GLP-1 agonist market still growing at a rapid pace, companies outside of the pharma industry are increasingly likely to benefit.
- Three potentially overlooked beneficiaries of GLP-1s may be TDOC, OLLI, and DXCM.
- TDOC and DXCM are health care firms providing telehealth services and continuous glucose monitoring devices, respectively, while OLLI is a bargain clothing store.
- Special Report: Everyone wanted SpaceX. Smart money wants this.
The GLP-1 revolution is quietly continuing even as investor interest has shifted to more timely topics. One of the best ways to gain exposure to the fast-growing weight loss drug space is through makers like Novo Nordisk (NYSE: NVO) or Eli Lilly (NYSE: LLY), the leading companies behind products such as Ozempic and Zepbound. There are, of course, less direct ways for investors to benefit from the GLP-1 rush as well. The prospect of the market tripling in size in the coming years has enticed a host of other drug developers to work toward their own offerings, and a number of up-and-coming pharma firms may be worth watching—or investors can look at dedicated exchange-traded funds (ETFs) like the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) for a broader view.
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776.
From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society.
His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Watch Porter Stansberry's full briefing and learn how to prepare now
But the impact of GLP-1 agonists is extending beyond the pharma space, and the companies below could benefit from this trend despite their lack of direct involvement. GLP-1 Telehealth Business Positioned to ThriveTeladoc Health (NYSE: TDOC) operates a telehealth platform that provides patients with virtual care services related to obesity management and metabolic health, among other services. These areas of Teladoc's business, along with GLP-1 prescription initiation, are growing particularly rapidly. The company makes it as easy as possible for qualified patients to gain access to GLP-1 treatment, which can be a game-changer for those without convenient access to in-person specialists. This has had a real impact on Teladoc's results. In Q1 2026, for instance, the firm beat revenue expectations by about $3 million at $614 million, and adjusted EBITDA of $58 million also came in ahead of guidance. Visit-based care is being enhanced by AI-enabled 24/7 offerings that will likely be a sales and margin driver throughout the rest of this year at least. At the same time, Teladoc is working to right its balance sheet by initiating a multi-step debt reduction process and planning to limit its stock-based compensation to $55 million or less in the coming year. The firm is also building its financial strength with a cash reserve that reached $751 million at the end of the first quarter. This is a welcome change for investors after several consecutive quarters of shaky financial health, as indicated by a TradeSmith health indicator in the red zone. GLP-1 Customers Buying New Wardrobes Might Fuel This Retailer's GrowthDiscount retailer Ollie's Bargain Outlet (NASDAQ: OLLI) may seem like an unlikely beneficiary of GLP-1 drugs, but this and similar clothing stores could play an increasingly important role for patients losing weight and needing to buy new clothes. Ollie's is among the most aggressive discount clothing retailers in terms of pricing and could be well-positioned to win business from GLP-1 patients seeking to replace a large volume of clothes quickly. For Q1 2026, Ollie's reported strong results overall, including sales growth of 14% year-over-year (YOY) and comparable store sales improvement of 1.7% over the same period. Adjusted earnings per share (EPS) increased by 21% YOY as well, despite headwinds including inflation and higher fuel prices. Ollie's is also expanding rapidly, with 27 new stores opening in the first quarter of the year and 75 new openings planned in total for this year. OLLI stock is a Moderate Buy across Wall Street, based on 14 Buy ratings and three Holds. Shares have fallen by almost 30% year-to-date (YTD) but still have about 60% upside potential based on analyst price targets. Glucose Monitoring Devices Could Surge in PopularityAlthough not a pharma company, health care sector peer DexCom (NASDAQ: DXCM) is a medical device firm that could benefit from the GLP-1 trend because of its continuous glucose monitoring (CGM) tools. CGMs are vital for GLP-1 patients with Type 2 diabetes, making these products a useful companion to GLP-1 treatment in some cases. Care providers may increasingly view CGMs and GLP-1s as a combined solution for patients with diabetes. CGMs have long been associated with insulin treatments, but the rapid expansion of GLP-1s beyond the population of patients with diabetes has the potential to open up monitoring needs for those interested in tracking glucose trends even if they are not also using insulin. DexCom has responded by launching over-the-counter products for a wider patient population. Overall, greater awareness of metabolic health and increased interest in tracking glucose levels could mean a surge in business for DexCom. This may contribute to DexCom's strong popularity among analysts: the stock has 22 Buy ratings compared to three Holds and one Sell, alongside 17% predicted upside potential. |
Post a Comment
0Comments